87 related articles for article (PubMed ID: 16474847)
1. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
Ellerhorst JA; Ekmekcioglu S; Johnson MK; Cooke CP; Johnson MM; Grimm EA
Oncogene; 2006 Jun; 25(28):3956-62. PubMed ID: 16474847
[TBL] [Abstract][Full Text] [Related]
2. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
[TBL] [Abstract][Full Text] [Related]
3. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Alsina J; Gorsk DH; Germino FJ; Shih W; Lu SE; Zhang ZG; Yang JM; Hait WN; Goydos JS
Clin Cancer Res; 2003 Dec; 9(17):6419-25. PubMed ID: 14695143
[TBL] [Abstract][Full Text] [Related]
4. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
5. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
[TBL] [Abstract][Full Text] [Related]
6. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
7. Spry2 expression correlates with BRAF mutation in thyroid cancer.
Xu L; Zhou JL; Cohen M; Bar-Sagi D; Patel KN
Surgery; 2010 Dec; 148(6):1282-7; discussion 1287. PubMed ID: 21134562
[TBL] [Abstract][Full Text] [Related]
8. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
[TBL] [Abstract][Full Text] [Related]
10. The naturally occurring biflavonoid, ochnaflavone, inhibits LPS-induced iNOS expression, which is mediated by ERK1/2 via NF-kappaB regulation, in RAW264.7 cells.
Suh SJ; Chung TW; Son MJ; Kim SH; Moon TC; Son KH; Kim HP; Chang HW; Kim CH
Arch Biochem Biophys; 2006 Mar; 447(2):136-46. PubMed ID: 16527246
[TBL] [Abstract][Full Text] [Related]
11. Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation.
Estrada Y; Dong J; Ossowski L
Pigment Cell Melanoma Res; 2009 Feb; 22(1):66-76. PubMed ID: 18983537
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
13. ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury.
Xu Z; Wang BR; Wang X; Kuang F; Duan XL; Jiao XY; Ju G
Life Sci; 2006 Oct; 79(20):1895-905. PubMed ID: 16978658
[TBL] [Abstract][Full Text] [Related]
14. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
15. Linoleic acid-induced expression of inducible nitric oxide synthase and cyclooxygenase II via p42/44 mitogen-activated protein kinase and nuclear factor-kappaB pathway in retinal pigment epithelial cells.
Fang IM; Yang CH; Yang CM; Chen MS
Exp Eye Res; 2007 Nov; 85(5):667-77. PubMed ID: 17825288
[TBL] [Abstract][Full Text] [Related]
16. A diarylheptanoid from lesser galangal (Alpinia officinarum) inhibits proinflammatory mediators via inhibition of mitogen-activated protein kinase, p44/42, and transcription factor nuclear factor-kappa B.
Yadav PN; Liu Z; Rafi MM
J Pharmacol Exp Ther; 2003 Jun; 305(3):925-31. PubMed ID: 12626645
[TBL] [Abstract][Full Text] [Related]
17. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
19. Novel protein kinase C-epsilon inhibits human CYP11B2 gene expression through ERK1/2 signalling pathway and JunB.
LeHoux JG; Lefebvre A
J Mol Endocrinol; 2006 Feb; 36(1):51-64. PubMed ID: 16461926
[TBL] [Abstract][Full Text] [Related]
20. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]